5th Circuit: FDA’s Post-2016 Mifepristone Actions Are Stayed Pending Appeal
NEW ORLEANS — A panel of the Fifth Circuit U.S. Court of Appeals on April 12 said anti-abortion plaintiffs are too late to challenge the Food and Drug Administration’s 2000 approval...To view the full article, register now.
Already a subscriber? Click here to view full article